Clinical Trials Logo

Refractory clinical trials

View clinical trials related to Refractory.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06424301 Not yet recruiting - Retinoblastoma Clinical Trials

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

Start date: May 21, 2024
Phase: Early Phase 1
Study type: Interventional

Retinoblastoma (RB) is the most common intraocular malignancy in children and accounts for 11% of all cancers in children under the age of 1 year. Although the incidence of RB is low, approximately 1/15,000 ~ 1/20,000, it tends to metastasize to the intracranial area through the optic nerve pathway leading to poor prognosis for patients with RB. Currently, with the emergence of new administration routes, such as intravitreal and intrarterial chemotherapy, the rate of eye preservation has been effectively improved. However, the use of high doses of chemotherapeutic agents may lead to visual impairments due to long-term retinal toxicity and some tumors recur or become resistant to chemotherapeutic agents after treatment. In such cases, ocular resection is the only option to prevent extraocular metastasis and death. Therefore, studies on retinoblastoma are currently focused on finding new targeted therapies to increase anti-tumor activity and reduce side effects. In this study, a novel targeting NUDT21 siRNA drug will be used to treat patients with refractory retinoblastoma. This drug promotes tumor apoptosis by regulating the 3'UTR plus tail of SMC1A, which makes the proliferative activity of tumor cells weaken and achieves tumor control. At the same time, since the targeted drug only focuses on tumor cells, it has reduced side effects compared with existing local chemotherapy regimens. Based on the above background, this study will explore the feasibility and effectiveness of intravitreal injection of NUDT21 siRNA in patients with refractory retinoblastoma through a two-center prospective study.

NCT ID: NCT06265545 Not yet recruiting - AML Clinical Trials

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

NCT ID: NCT06038422 Not yet recruiting - Recurrence Clinical Trials

GTP Regimen in the Treatment of Refractory/Recurrent HLH

Start date: September 15, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are: - Overall remission rate of GTP regimen in R/R HLH - Adverse effect of GTP regimen Participants will be treated with GTP regimen

NCT ID: NCT04599452 Not yet recruiting - Elderly Clinical Trials

NK Cell Therapy Recurrent/Refractory Elderly AML

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.